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Diabetes and renal functiona b s t r a c t
This study aimed at assessing the effects of Keﬁr, a probiotic fermented milk, on oxidative stress in dia-
betic animals. The induction of diabetes was achieved in adult male Wistar rats using streptozotocin
(STZ). The animals were distributed into four groups as follows: control (CTL); control Keﬁr (CTLK); dia-
betic (DM) and diabetic Keﬁr (DMK). Starting on the 5th day of diabetes, Keﬁr was administered by daily
gavage at a dose of 1.8 mL/day for 8 weeks. Before and after Keﬁr treatment, the rats were placed in indi-
vidual metabolic cages to obtain blood and urine samples to evaluate urea, creatinine, proteinuria, nitric
oxide (NO), thiobarbituric acid reactive substances (TBARS) and C-reactive protein (CRP). After sacriﬁcing
the animals, the renal cortex was removed for histology, oxidative stress and NOS evaluation. When com-
pared to CTL rats, DM rats showed increased levels of glycemia, plasmatic urea, proteinuria, renal NO,
superoxide anion, TBARS, and plasmatic CRP; also demonstrated a reduction in urinary urea, creatinine,
and NO. However, DMK rats showed a signiﬁcant improvement in most of these parameters. Despite the
lack of differences observed in the expression of endothelial NO synthase (eNOS), the expression of induc-
ible NO synthase (iNOS) was signiﬁcantly lower in the DMK group when compared to DM rats, as
assessed by Western blot analysis. Moreover, the DMK group presented a signiﬁcant reduction of glyco-
gen accumulation within the renal tubules when compared to the DM group. These results indicate that
Keﬁr treatment may contribute to better control of glycemia and oxidative stress, which is associated
with the amelioration of renal function, suggesting its use as a non-pharmacological adjuvant to delay
the progression of diabetic complications.
 2014 Elsevier Inc. All rights reserved.Introduction lead to the increased production of reactive oxygen speciesDiabetes mellitus has become a serious public health problem
that affects millions of individuals worldwide. The World Health
Organization predicts that 439 million people will have this
disease in 2030, and Brazil was listed 5th of 10 countries estimated
to have the highest number of people with diabetes, affecting
approximately 12.7 million Brazilians in 2030 [1].
Hyperglycemia and oxidative stress have been closely linked to
diabetic complications, such as neuropathy, retinopathy and
nephropathy. Additionally, excessively high blood glucose levels(ROS), such as hydrogen peroxide and superoxide radicals [2]. A
chronic hyperglycemic state may also cause ROS increases via glu-
cose auto-oxidation in various tissues, leading to high oxidative/
nitrosative stress with subsequent impaired nitric oxide (NO) bio-
availability. NO is a potent, endogenous vasodilator that modulates
renal function and plays a key role in endothelial dysfunction [3].
High levels of ROS contribute to lipid peroxidation (LPO) in
cellular membranes, increasing their ﬂuidity and permeability.
Speciﬁcally, high levels of ROS generate malondialdehyde (MDA),
a highly toxic molecule, and its secondary product, thiobarbituric
acid reactive substances (TBARS), which is used as marker of LPO
[4]. ROS are also responsible for the activation of nuclear factor-
kappa B (NF-jB), which increases the expression of pro-inﬂamma-
tory biomarkers, such as tumor necrosis factor-alpha (TNF-a), and
interleukin-6 (IL-6), which augments the expression of C-reactive
protein (CRP) [5].
54 G.R. Punaro et al. / Nitric Oxide 37 (2014) 53–60Keﬁr is a beverage made from milk that is fermented by a com-
plex mixture of bacteria, including various species of lactobacilli
and yeasts. It has been considered a probiotic due to its antioxidant
and anti-inﬂammatory properties [6,7]. In this study, we investi-
gated the effects of Keﬁr on the production of nitric oxide and
oxidative stress and renal damage in STZ-induced diabetic rats.Material and methods
Animals
MaleWistar rats, 8 weeks of age,weighing ±250 g,were obtained
from Central Animal Housing, Sao Paulo, Brazil. All protocols were
approved by the Ethics Committee in Research of Universidade
Federal de Sao Paulo (protocol #1335/09). The animals were
maintained in the Animal Housing of Nephrology Division at a tem-
perature of 22 ± 1 C and at a light–dark cycle of 12/12 h, beginning
at 6:00 am. The animals were given free access to standard chow
(Nuvital CR-1,Nuvilab, Colombo, PR, Brazil) andwater. The ratswere
allocated into the four following groups: CTL (n = 9, control group);
CTLK (n = 9, control group that received Keﬁr); DM (n = 12, diabetic
group) and DMK (n = 12, diabetic group treated with Keﬁr).
Induction of type 1 diabetes
After seven days of adaptation, 9-week-old animals received a
single intravenous administration of STZ 45 mg/kg dissolved in
0.1 M cold citrate buffer, pH 4.5. The controls rats only received
citrate buffer. After 72 h of induction, glycemia was measured in
blood samples collected fromthe tail vein and thevaluesweredeter-
mined using a glucometer. DM was deﬁned in this study as fasting
blood glucose P200 mg/dL and animals that failed to meet this
criteriawereexcluded.The fastingbloodglucose (3 h)of eachanimal
was measured during 8 weeks protocol for monitoring diabetes.
Production and preparation of Keﬁr
The ingredients used were as follows: milk: skim milk powder
Molico (Nestle, Sao Paulo, Brazil); lactic culture: Keﬁr (1010 CFU/g
of lactic acid bacteria and 104–107 CFU/g of yeast), containing Lacto-
coccus lactis subsp., Leuconostoc sp., Streptococcus termophilus,
Lactobacillus sp., Keﬁr yeast, and Keﬁr grains microﬂora that are not
genetically modiﬁed, according to European Parliament (Danisco
Biolacta, Olstyn, Poland). The preparation of the matrix was carried
out as follows: skim milk powder was reconstituted to 10% with
distilledwater andwas incubated at 85 C for 15 min (LaudaWobser
GMBH & CO. KG type A100, Lauda-Königshofen, Germany) using a
mechanical shaker (Quimis Q250M1, Diadema, SP, Brazil). Subse-
quently, 20 mg freeze-dried Keﬁr culture was added to 100 mL of
the treated milk and fermentation was carried out at 23 C for
16 h. This was monitored by the Cinac System (Cynetique d´acidiﬁ-
cation, Ysebaert, Frépillon, France) [8]. When the desired pH of 4.6
was reached, the fermentation was stopped by cooling the ﬂasks in
ice bath, and storing them under refrigeration at 4 C until utiliza-
tion. Keﬁr was prepared as described above, once a week, thus
ensuring freshness of the product. All procedures were performed
at the Laboratory of Food Technology, Faculty of Pharmaceutical
Sciences, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Keﬁr treatment
The CTLK and DMK groups received Keﬁr starting on the 5th day
after diabetes induction. Administration was carried out for
8 weeks by gavage, at a dose of 1.8 mL/day. The other groups,
CTL and DM, received water as a control. All animals were placedin individual metabolic cages for 24 h prior to and after the treat-
ment protocol, with water and food ad libitum, for urine collection.
After this period, the rats were fasted for 3 h, after which a blood
sample was collected from the retro-orbital plexus while the rats
were under anesthesia. For anesthesia, intramuscular injection of
ketamine chloridrate (67 mg/kg) and xylazine chloridrate (8 mg/
kg) was used. All samples were stored in freezer at 20 C. At
the end of protocol, the animals were killed by CO2, followed by
exsanguination and the removal of the kidneys.
Oral glucose tolerance test (OGTT)
After 8 weeks of Keﬁr treatment, OGTT was performed in the
animals. After 12 h of fasting, the animals were orally fed a 20%
glucose solution (1 g/kg) and their blood glucose concentrations
were determined at 0, 30, 60 and 120 min intervals using a
glucometer.
Renal function assessment
The plasma and urinary urea concentrations were estimated by
urea kit CE. Creatinine was measured by colorimetric assay
creatinine kit and proteinuria was evaluated by sensiprot kit.
Kidney histology
The kidneys were ﬁxed in 10% formaldehyde, embedded in
parafﬁn, sectioned at 4 lm thickness and stained with periodic
acid–Schiff reagent (PAS). The histological changes in the stained
sections were assessed by a nephrologist under a light microscope
at 400 magniﬁcation. This was carried out under blinded condi-
tions and for each kidney, 6 randomly selected areas of cortex were
photographed. The area of each renal cortex was digitalized by an
imaging program and a count was made according to changes in
the tubules.
Estimation of oxidative stress and inﬂammatory parameters
Kidney tissue homogenate
Homogenates of the renal cortex were prepared as previously
described [9]. The homogenates were used for NO, superoxide
anion and LPO assays and the protein content was analyzed by
Bradford assay.
NO measurement
NO was measured to evaluate the magnitude of vascular dam-
age and oxidative stress of diabetic rats in plasma, urine and renal
cortex. Because NO is extremely unstable, we used a method in
which the stable NO metabolites, nitrite and nitrate, were re-con-
verted to NO through a reaction with vanadium. The NO that was
generated was quantiﬁed by a chemiluminescence method using
the Nitric Oxide Analyzer (Sievers Instruments, Boulder, USA), a
high-sensitive detector of NO in liquid samples (1 pmol) that is
based on the gas-phase chemiluminescent reaction between NO
and ozone [10].
Western blot analysis
The protein expression of endothelial nitric oxide synthase
(eNOS) and inducible nitric oxide synthase (iNOS) were assessed
in the kidney samples that were individually homogenized with
a Polytron in K-HEPES buffer containing a mixture of protease
inhibitors. After incubation at 4 C for 15 min, the samples were
centrifuged at 2000g. The protein concentrations were quantiﬁed
using the Bradford assay method and the 80 lg of protein from
each sample was separated on an 8% polyacrylamide gel and
transferred to a nitrocellulose membrane. Subsequently, the mem-
branes were probed with a mouse monoclonal eNOS (1:1000) or a
G.R. Punaro et al. / Nitric Oxide 37 (2014) 53–60 55rabbit polyclonal iNOS (1:200) primary antibody, followed by anti-
mouse (1:1000) or anti-rabbit (1:5000) secondary antibody,
respectively. The bands were visualized using a chemilumines-
cence substrate and analyzed by gel documentation Alience 4.7
Uvitec (Cambridge, Cambs, UK). The relative expression of NOS
proteins in each kidney were normalized using actin antibody
and the values are expressed as a percentage of normal protein
expression.Superoxide anion
The level of the superoxide anion in the renal cortex was de-
tected indirectly according to the adapted nitroblue tetrazolium
(NBT) protocol. The optical density (OD) was read in microplate
reader at 560 nm [11].LPO estimation
The LPO was estimated in terms of MDA by using the TBARS
method. The MDA concentration was calculated using a molar
extinction coefﬁcient of 1.56  105 mol1 cm1 in plasma, urine
and renal cortex [12] at the end of the Keﬁr treatment.CRP measurement
To determine the plasmatic CRP, we utilized the turbidimetric
technique [13].Table 1
Metabolic proﬁle, renal function, and oxidative stress in animals before Keﬁr
treatment.
Parameters CTL DM
n = 18 n = 24
Water intake (mL/24 h) 29.9 ± 0.9 80.2 ± 4.9b
Chow intake (g/24 h) 19.1 ± 0.4 23.9 ± 0.9b
Diuresis (mL/24 h) 13.0 ± 0.7 61.1 ± 4.6b
Weight (g) 269.8 ± 5.2 253.7 ± 4.0aReagents
Streptozotocin was purchased from Sigma Chemical (St. Louis,
MO, USA). Citric acid was acquired from LabSynth (Sao Paulo, SP,
Brazil) for preparation of the citrate buffer. For the OGTT test, the
Accu-chek advantage II glucometer strips were purchased from
Roche Diagnostics (Mannheim, Baden-Württemberg, Germany)
and glucose D anidra was obtained from LabSynth (Sao Paulo, SP,
Brazil). The Dopalen (ketamine chloridrate) and Anasedan (xyla-
zine chloridrate) anesthetics were obtained from Sespo (Sao Paulo,
SP, Brazil). The creatinine, urea and proteinuria assay kits were
obtained from Labtest (Lagoa Santa, MG, Brazil). Vanadium was
purchased from Sigma Chemical (St. Louis, MO, USA). Trichloroace-
tic was obtained from LabSynth (Sao Paulo, SP, Brazil) and thiobar-
bituric acid was purchased from J.T. Baker Chemical (Phillipsburg,
NJ, USA). Nitroblue tetrazolium chloride (NBT) was obtained from
Amresco (Solon, OH, USA). HEPES was purchased from USB
Corporation (Cleveland, OH, USA) and the K-HEPES buffer
contained 200 mM mannitol, 80 mM HEPES and 41 mM KOH, pH
7.5. Protease inhibitors cocktailI was acquired from Millipore
(Billerica, MA, USA). Mouse anti-eNOS was obtained from Abcam
(Cambridge, Cambs, UK), rabbit anti-iNOS and actin were obtained
from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). The
enhanced chemiluminescence (ECL) Western blotting analysis
system was obtained from Amersham International, Plc (Little
Chalfont, Bucks, UK).Fasting blood glucose (mg/dL) 91.8 ± 3.5 293.5 ± 12.3b
Plasmatic urea (mg/dL) 29.2 ± 1.9 55.6 ± 4.6b
Urinary urea (mg/dL) 7,556 ± 444 2,403 ± 129b
Plasmatic creatinine (mg/dL) 0.70 ± 0.04 0.90 ± 0.02b
Urinary creatinine (mg/dL) 166.8 ± 28.0 62.8 ± 14.7b
Proteinuria (nmol/24 h) 11.2 ± 0.6 21.4 ± 1.0b
Plasmatic NO (lM) 89.7 ± 12.2 58.9 ± 9.0a
NO excretion (lmol/24 h) 15.9 ± 2.7 1.4 ± 0.2b
Plasmatic TBARS (nmol/mL) 3.03 ± 0.06 3.17 ± 0.06
TBARS excretion (nmol/24 h) 86.9 ± 5.3 192.4 ± 10.4b
Values are expressed as means ± SEM. Unpaired t or Mann Whitney test. Control
(CTL); diabetic (DM).
a p < 0.05.
b p < 0.001 vs CTL.Statistical analysis
The results were expressed as the mean ± standard error media
(SEM). The differences among the four groups were examined for
statistical signiﬁcance using one-way analysis of variance (ANOVA)
followed by Newman–Keuls Multiple Comparison post test or by
Kruskal–Wallis followed by Dunn’s Multiple Comparison post test.
The differences between two groups were analyzed by unpaired t
or Mann Whitney tests, as appropriate. The correlation was
analyzed by Sperman rank coefﬁcient. Values were considered
statistically signiﬁcant when p < 0.05.Results
Metabolic proﬁle, renal function, and oxidative stress before Keﬁr
treatment
The parameters of the rats after the 5th day of diabetes induc-
tion are shown in Table 1. DM animals demonstrated signiﬁcant
differences in all parameters, except for plasmatic TBARS. These
animals showed signiﬁcant increases in water and chow intake,
diuresis, fasting blood glucose, plasmatic urea and creatinine, and
excretion of proteinuria and TBARS. In contrast, DM rats had a de-
crease in body weight, urinary urea and creatinine, and plasmatic
and urinary NO when compared to CTL rats.
The changes in metabolic variables, renal function, and oxida-
tive stress after 8 weeks of Keﬁr treatment are shown in Table 2.
Keﬁr administration did not cause difference in any of these
parameters in the CTLK group. The control and diabetic groups
showed signiﬁcant differences in the following parameters: water
and chow intake, diuresis and weight gain. However, in the DMK
group, these parameters were signiﬁcantly decreased when
compared to the DM group; an exception was weight gain, which
was higher in DMK animals than in DM animals.
Glycemia
The levels of glycemia after Keﬁr treatment are shown in
Fig. 1A. On the 5th day after diabetes induction (0), the fasting
blood glucose level was increased in DM rats when compared to
CTL rats (293 ± 21 vs 89 ± 5, p < 0.001) and in DMK rats when com-
pared to CTLK rats (294 ± 14 vs 95 ± 5, p < 0.001). After the 8th
week of Keﬁr treatment, these levels were reduced in DMK rats
when compared to DM rats (325 ± 32 vs 457 ± 31, p < 0.001). In
contrast, during OGTT, as shown in Fig. 1B, it was observed that
glycemia in the DMK group was decreased after 30, 60 and
120 min when compared to DM, although this was only signiﬁcant
after 30 min (344 ± 37 vs 221 ± 51, p < 0.05).
Renal function
As shown in Table 2, the levels of plasmatic urea were increased
in DM rats when compared with CTL rats and in the DMK group
when compared to the CTLK group. However, this was reduced in
DMK rats when compared with DM rats. The concentration of
urinary urea was four times lower in the DM group than in the
Table 2
Metabolic proﬁle, renal function, and oxidative stress of the groups after Keﬁr treatment.
Variables CTL CTLK DM DMK
Water intake (mL/24 h) 24.8 ± 1.8 25.8 ± 3.7 124.4 ± 12.4a 94.1 ± 14.4b,c
Chow intake (g/24 h) 17.3 ± 0.6 19.1 ± 1.0 36.9 ± 2.0a 30.6 ± 2.3b,c
Diuresis (mL/24 h) 13.1 ± 1.0 13.7 ± 0.7 90.9 ± 9.0a 70.9 ± 9.4b,c
Weight (D) 67.5 ± 4.4 69.3 ± 1.6 25.3 ± 4.5a 35.3 ± 5.9b
Plasmatic urea (mg/dL) 31.9 ± 1.4 36.2 ± 2.5 58.5 ± 3.6a 47.6 ± 2.4b,c
Urinary urea (mg/dL) 8,691 ± 343 8,423 ± 229 2,006 ± 142a 2,996 ± 322b,c
Plasmatic creatinine (mg/dL) 0.71 ± 0.05 0.72 ± 0.04 0.75 ± 0.03 0.78 ± 0.05
Urinary creatinine (mg/dL) 131.7 ± 9.2 127.9 ± 4.5 33.2 ± 5.6a 34.8 ± 7.8b
Proteinuria (nmol/24 h) 10.4 ± 0.8 11.2 ± 0.7 25.5 ± 3.7a 21.0 ± 2.8b
Plasmatic NO (lM) 66.6 ± 4.3 77.8 ± 6.6 79.2 ± 5.0 76.5 ± 5.4
NO excretion (lmol/24 h) 14.9 ± 3.6 17.5 ± 3.8 2.1 ± 0.7a 16.4 ± 4.9
Plasmatic TBARS (nmol/mL) 3.32 ± 0.06 3.16 ± 0.08 3.79 ± 0.10a 3.58 ± 0.17
TBARS excretion (nmol/24 h) 81.6 ± 2.1 84.4 ± 4.3 300.4 ± 18.9 a 248.9 ± 19.2b,c
Values are expressed as mean ± SEM. One-way ANOVA followed by Newman–Keuls Multiple Comparison post test. Control (CTL); control Keﬁr (CTLK); diabetic (DM); diabetic
Keﬁr (DMK); n = 9–12/group.
a p < 0.001 vs CTL.
b p < 0.01 vs CTLK.
c p < 0.05 vs DM.
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Fig. 1. (A) Glycemia levels after 0, 2, 4 and 8 weeks during Keﬁr treatment, n = 9–
12. (B) Glycemia levels during oral glucose tolerance test (OGTT), n = 4–6/group.
Control (CTL); control Keﬁr (CTLK); diabetic (DM); diabetic Keﬁr (DMK). Values are
expressed as means ± SEM. One-way ANOVA followed by Newman–Keuls Multiple
Comparison post test. &p < 0.05, &&&p < 0.001 vs CTL; ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄-
p < 0.001 vs CTLK; #p < 0.05, ###p < 0.001 vs DM.
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Fig. 2. (A) Renal histology after Keﬁr treatment. Kidneys showed glycogen storage
in diabetic rats tubules (shown by arrows). (B) Average glycogenated tubules
represented graphically in each group. Control (CTL); control Keﬁr (CTLK); diabetic
(DM); diabetic Keﬁr (DMK), n = 3/group. Values are expressed as means ± SEM. One-
way ANOVA followed by Newman–Keuls Multiple Comparison post test.
&&&p < 0.001 vs CTL; ⁄⁄⁄p < 0.001 vs CTLK; ###p < 0.001 vs DM.
56 G.R. Punaro et al. / Nitric Oxide 37 (2014) 53–60CTL group, while in the DMK group, it was 2.8 times lower than in
the CTLK group, demonstrating that this parameter was increased
in the DMK group when compared to the DM group. Moreover,
plasmatic creatinine was not different among control and diabetic
animals, and urinary creatinine and proteinuria were not different
between DMK and DM groups.
In relation to renal histology, the diabetic groups presented
with an accumulation of glycogen in the renal tubules. This was re-
duced in the DMK group when compared to the DM group (9 ± 1 vs
13 ± 1, p < 0.001), as demonstrated in Fig. 2).Oxidative stress and inﬂammatory state
According to Table 2, there was no difference in plasmatic NO
levels in the animals studied. However, the excretion of NO inDM rats was signiﬁcantly reduced by 7 times when compared to
CTL rats and in DMK rats, this parameter was higher compared
to DM rats, but did not show any difference when compared to
CTLK rats. Interestingly, the data demonstrated a strong and in-
verse correlation between NO and proteinuria excretion, which is
an early marker of renal lesion, among the control and diabetic
groups (r = 0.83, p < 0.001), as shown in Fig. 3A.
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Keﬁr treatment. Sperman rank coefﬁcient r = 0.83, p < 0.001. (B) NO in renal
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Fig. 4. (A) Representative image of Western blot analysis of eNOS and iNOS in renal
cortex of control and diabetic rats after Keﬁr treatment. (B) NOS expression
represented graphically after actin housekeeping normalization; n = 4–5/group.
Diabetic (DM); diabetic Keﬁr (DMK). Values are expressed as means ± SEM. One-
way ANOVA followed by Newman–Keuls Multiple Comparison post test. NS: non
signiﬁcant. #p < 0.05 vs DM.
G.R. Punaro et al. / Nitric Oxide 37 (2014) 53–60 57The level of NO in the renal cortex was higher in DM rats when
compared to CTL rats (13 ± 2 vs 3 ± 0.4, p < 0.05), but reduced in
DMK rats compared to DM rats (5 ± 2, p < 0.05). This is shown in
Fig. 3B. The Western Blot analysis of the renal cortex showed that
there was no difference in eNOS expression in the DM and DMK
rats. However, there was a signiﬁcant reduction in the expression
of iNOS in the DMK group when compared to the DM group
(101 ± 2 vs 113 ± 5, p < 0.05), as shown in Figs. 4A and B.
Likewise, a similar increase in superoxide anion (OD) was
observed in the renal cortex of DM rats when compared to CTL
rats (0.107 ± 0.012 vs 0.023 ± 0.007, p < 0.001). However, DMK rats
presented with lower values in this parameter than DM rats
(0.047 ± 0.019, p < 0.01), and in the DMK rats, this value
approached that of the CTLK rats (0.021 ± 0.002, NS), as seen in
Fig. 5A.
In Table 2, we observed that plasmatic TBARS was higher in the
DM group however, not demonstrated difference between DMK
and CTLK; otherwise, the excretion of TBARS at the end of Keﬁr
treatment was different among the groups, and the main differ-
ences were observed between the control and diabetic animals.
The excretion of TBARS was three times higher in the diabetic
groups when compared to the respective control groups. Notably,
a signiﬁcant reduction was observed in the DMK group when
compared to DM and these values approached of the CTLK group
(Table 2). There was also an increase in TBARS in the renal cortex
of diabetic animals. However, as shown in Fig. 5B, this elevation
was more pronounced in the DM group compared to the CTL group
(0.65 ± 0.06 vs 0.22 ± 0.04, p < 0.001).
The CRP concentration in the DM group was signiﬁcantly in-
creased when compared to the CTL group (0.28 ± 0.01 vs 0.18
± 0.04, p < 0.05). The DMK group showed a reduction of this
parameter compared to the DM group (NS) and an increase when
compared to the CTLK group (0.23 ± 0.03 vs 0.16 ± 0.01, NS)
(Fig. 5C).Discussion
STZ-induced hyperglycemia is a recognized experimental model
that is used to study both type 1 and type 2 diabetes [14]. In this
study, a lower dose of STZ (45 mg/kg) was used and the rats
became permanently diabetic. This allowed the production of a
diabetic state with moderate to severe hyperglycemia throughout
the protocol. Among the most important ﬁndings in this study,
Keﬁr treatment in diabetic rats resulted in better glycemic control
with reduced polyuria, polydipsia and polyphagia, a partial
improvement in renal function, increased NO excretion and reduc-
tion of superoxide anion, LPO and inﬂammation.
The mechanisms by which probiotic bacteria modulate hyper-
glycemia are not fully understood, although previous studies have
reported that supplementation with a strain of Lactobacillus signif-
icantly delayed the onset of glucose intolerance, hyperglycemia,
hyperinsulinemia, and oxidative stress in rats with type 2 diabetes
and also reduced the risk of the development of associated
complications [15,16].
Additionally, studies that utilized animals fed with Keﬁran, an
exopolysaccharide isolated from Keﬁr grains, demonstrated that
it reduced blood pressure and serum cholesterol in stroke-prone
spontaneously hypertensive rats (SHR-SP) [17] and reduced ath-
erosclerosis in rabbits with type 2 diabetes [18]. It also decreased
the blood glucose levels in a genetic diabetic animal model (KKAy)
that showed impaired glucose tolerance to an intraperitoneal
glucose administration [19].
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Fig. 5. (A) Optical density (OD) of superoxide anion in renal cortex after Keﬁr
treatment. (B) Thiobarbituric acid reactive substances (TBARS) in renal cortex. (C)
Plasma C-reactive protein (CRP) levels, n = 5–8 per group. Control (CTL); control
Keﬁr (CTLK); diabetic (DM); diabetic Keﬁr (DMK). Values are expressed as
means ± SEM. One-way ANOVA followed by Newman–Keuls Multiple Comparison
post test. &&&p < 0.001, &p < 0.05 vs CTL; ##p < 0.01 vs DM.
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the intestinal immune system and inﬂuence intestinal physiology.
This was observed in an in vivo study using healthy female rats that
consumed a Keﬁr-supplemented diet. Keﬁr supplementation was
shown to have an effect on enzymes and proteins, increase the
activity of the intestinal dipeptidase and decrease the Na+-depen-
dent uptake of intestinal sugar, which contributes to protein
digestion and glycemia reduction, respectively [20].
Hyperglycemia is the main factor in the progression of DN,
leading to the dysfunction of multiple organs and increasing the
morbidity and mortality in patients with diabetes [21]. In our
study, the kidneys of the diabetic animals were injured when com-
pared to control animals, but after Keﬁr administration, this was
partially improved. This is in agreement with the literature, where
it has been previously reported that probiotic bacteria beneﬁtted
both human and animals with kidney failure by increasing gut
bacterial metabolism for the excretion of ammonia, thus reducing
blood urea-nitrogen levels [22,23].In the present investigation, we observed signiﬁcant proteinuria
in diabetic rats, suggesting increased permeability of the glomeru-
lar basement membrane [24], but this was not signiﬁcantly
reduced in the Keﬁr-supplemented group. Nevertheless, we ob-
served a strong and inverse correlation between proteinuria and
NO among control and diabetic animals. This shows the impor-
tance of NO on this parameter, a matter which is still controversial
[3] but has been reproduced in our previous study [9]. Moreover,
glycogen accumulation was observed in the kidney tubules of
DM rats and this alteration was signiﬁcantly reduced after Keﬁr
treatment, most likely as a consequence of better glycemic control
in these animals.
The bioavailability of vascular NO is decreased in diabetes, both
in human and animals, possibly due to elevated oxidative stress
stimulated by the chronic hyperglycemic state [25]. This is because
NO can be inactivated by reaction with superoxide, resulting in
peroxynitrite, or may be transformed into the more stable hydro-
gen peroxide radical [3,14]. In this study, superoxide anion, one
of the main types of ROS, was higher in the renal tissue of the
DM group and was signiﬁcantly reduced in the DMK group. These
ﬁndings agree with that reported by Ishii et al., who showed that
NOS activity is augmented in the kidney cortex of diabetic rats
and as such, larger quantities of superoxide are produced [26].
In the present investigation, NO excretion was reduced in
diabetic animals in comparison to their respective control and
was increased after Keﬁr treatment to control levels. Another study
showed the role of some probiotic bacteria in the generation of
local NO in the intestinal lumen by nitrate reduction or acid depen-
dent mechanisms, which may be counteracted by rapid NO
consumption by other strains or diffused into the surrounding
tissues. This may explain some of the health promoting effects of
these bacteria, for example, by potentiating the antimicrobial
property of NO [27,28].
Moreover, the increase in blood glucose concentration activates
high expression of iNOS through NF-kB. This is followed by the
increased production of NO, which inﬂuences several signal path-
ways [29]. This up regulation of iNOS under conditions of oxidative
stress may be a compensatory mechanism for reduced NO
availability, indicating roles for NO, ROS, and peroxynitrite in the
development of early diabetic damage prior to the development
of complications [30].
Furthermore, researchers have shown that the uncoupling of
eNOS by peroxynitrite may be a secondary mechanism by which
hyperglycemia can quench and/or inactivate NO and consequently,
lead to endothelial dysfunction [30,31]. However, in this study,
there was a reduction of eNOS expression in both groups, DM
and DMK, when compared to CTL and CTLK, although there was
no difference between them. Nevertheless, in DM animals, higher
iNOS expression was observed, and this was accompanied by
elevated oxidative stress in the renal cortex, as reﬂected by an
increase in NO-scavenging superoxide anions and MDA. This sug-
gests that in the diabetic kidney, NO is deﬁcient and consequently,
its bioavailability is reduced [3,32]. This status was reversed in
DMK animals, which showed reduced oxidative stress and iNOS
and the restoration of NO excretion.
The measurement of LPO was based on the extinction coefﬁ-
cient of MDA, which is the end product of fatty acid peroxidation
that reacts with thiobarbituric acid (TBA). This is accepted as an in-
dex of LPO and is widely utilized in studies relating to diabetes [4].
It has also been demonstrated that MDA in the urine is a more sen-
sitive measure than that in the plasma [33], a ﬁnding that supports
previous published results of our research group [9].
In the present study, there was a signiﬁcant increase of LPO in
diabetic rats, most likely due in part to the elevation in blood
glucose levels that generate ROS upon auto oxidation [2]. This
indicates that peroxidative injury may be involved in the reduction
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diabetic complications. In our study, Keﬁr treatment signiﬁcantly
decreased LPO, and this was accompanied by a reduction in hyper-
glycemia, perhaps by the preservation of pancreatic b-cells, which
are vulnerable to oxidative damage [14], or by the antioxidant
effect of fermented milk. It is known that the bioactive peptides
released during fermentation by proteolytic lactic acid bacteria
can scavenge the ROS and inhibit LPO [34].
In contrast, CRP, a recognized marker of inﬂammation
associated with endothelial dysfunction, is elevated in the blood
of patients with both type 1 [35] and type 2 diabetes [36].
Researchers have reported no change [37] or an increase [21] in
plasmatic CRP levels in STZ-treated diabetic rats. In this study, a
signiﬁcant increase in plasmatic CRP was observed in diabetic rats;
however, this parameter was decreased after Keﬁr treatment, per-
haps due to the better control of hyperglycemia in these animals,
which could modulate the activation of NF-jB and reduce the iNOS
expression. It was demonstrated that Keﬁr could inhibit the innate
response of intestinal epithelial cells, suggesting the modulation of
the NF-jB pathway [38].
Furthermore, other studies have shown that altered bowel
function contributes to the development of diabetes mellitus. In
particular, the intestinal barrier has become a focus of much
research because increased intestinal permeability has been asso-
ciated with type 1 and type 2 diabetes; suggesting that this would
precede the onset of clinical diabetes in humans and rats and that
enhancing intestinal barrier function may be important for pre-
venting pathophysiological mechanisms in diabetic patients [39,40].
Studies with probiotics could be used to design clinical plans for
prevention-based treatment in which microbiota could be beneﬁ-
cial in the attenuation or delay of disease progression [41]. While
the effects and the precise mechanisms of probiotics involved in
the diabetes remain unknown, they are likely related to a decrease
in oxidative stress that is associated with the immune-modulatory
and anti-inﬂammatory properties of these bacteria, the modiﬁca-
tion of intestinal microbiota and maintenance of gut integrity.
Further studies are necessary to provide new insights into the
effective therapeutic approaches for type 1 diabetes mellitus.
Conclusion
The results obtained in this study show that Keﬁr treatment sig-
niﬁcantly reduced the progression of STZ-induced hyperglycemia
and oxidative stress in rats. Thus, Keﬁr may play a role in slowing
the metabolic changes that contribute to DN.
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